No Data
No Data
Shareholders 26% Loss in Zhejiang Jianfeng Group (SHSE:600668) Partly Attributable to the Company's Decline in Earnings Over Past Year
Zhejiang Jianfeng Group (600668.SH): Participating subsidiaries plan to prepare significant events.
On August 1st, Gelunhui reported that Zhejiang Jianfeng Group (600668.SH) received a notification from its equity investment subsidiary, Tasly Biopharmaceutical Industry Group Co., Ltd. (hereinafter referred to as Tasly Group), stating that it is planning a share transfer concerning its controlling subsidiary Tasly Pharmaceutical Group Co., Ltd. (Stock code: 600535, Stock abbreviation: Tasly). This matter may lead to a change in the controlling rights of Tasly Pharmaceutical Group Co., Ltd. The company holds a 20.76% stake in Tasly Group, which is its associated enterprise and a long-term equity investment accounted for by the equity method.
Zhejiang Jianfeng Group (600668.SH): The new specification of esomeprazole magnesium enteric-coated granules has been approved.
Zhejiang Jianfeng Group (600668.SH) announced that the controlling subsidiary of its wholly-owned subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., ...
Zhejiang Jianfeng Group's announcement of a decrease in performance for the first half of 2024.
Zhejiang Jianfeng Group (600668.SH) is expected to have a net income decrease of 49.83% to 65.96% in the first half of the year.
On July 9th, Gelunhui reported that Zhejiang Jianfeng Group (600668.SH) announced that based on preliminary calculations by the finance department, it is expected to achieve a net income of 38 million to 56 million yuan attributable to shareholders of the listed company in the first half of 2024. Compared with the same period last year, it will decrease by 55.6218 million to 73.6218 million yuan, a year-on-year decrease of 49.83% to 65.96%. It is expected to achieve a net income after deducting non-recurring gains and losses attributable to shareholders of the listed company of 30 million to 45 million yuan in the first half of 2024, a decrease of 56.6971 million yuan compared to the same period last year.
Zhejiang Jianfeng Group (600668.SH): Oseltamivir phosphate capsules has obtained the pharmaceutical registration certificate.
On July 5th, Gelonhui reported that Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as Jianfeng Pharmaceutical), a wholly-owned subsidiary of Zhejiang Jianfeng Group (600668.SH), received the approval and issuance of the registration certificate for oseltamivir phosphate capsules from the National Medical Products Administration (certificate number: 2024S01534). This means that Jianfeng Pharmaceutical is qualified to produce and sell this pharmaceutical, which will further enrich its product variety and help enhance the company's competitiveness in the pharmaceutical business.
No Data